CAR T- cell therapy for breast cancer is on the cards

Share This Post

March 2022: According to researchers at the UNC Lineberger Comprehensive Cancer Center, adding a tiny chemical to a treatment process called chimeric antigen receptor-T (CAR-T) cell therapy can boost immune system T cells to successfully attack solid tumours like breast malignancies. The boost aids in the recruitment of more immune cells to the tumour location. Journal of Experimental Medicine published the findings. Apart from this study there are numerous ongoing clinical trials and seems CAR T-cell therapy for breast cancer is on cards and should be available very soon.

 

CAR T cell therapy in breast cancer

CAR-T immunotherapy, in which T cells are genetically modified to express chimeric antigen receptors (CARs), which then target surface proteins on cancer cells, has proven to be the most successful treatment for B-cell leukaemia and lymphoma patients. However, new research conducted in animal models suggests that CAR-T therapy could be beneficial against solid tumours as well.

“We know that CAR T cells are safe for patients with solid tumours, but they haven’t been able to cause significant tumour regression in the vast majority of people treated,” said Jonathan S. Serody, MD, the Elizabeth Thomas Professor of Medicine, Microbiology, and Immunology and director of UNC Lineberger’s Immunotherapy Program. We may now have a novel strategy to getting CAR T cells to work in solid tumours, which we believe might be a game-changer for cancer therapy targeting a large variety of diseases.

The paper’s corresponding author is Serody, and the first author is Nuo Xu, PhD, a former graduate student at UNC Lineberger and UNC School of Medicine.

T cells infused back into patients must be able to travel to the tumour location for CAR-T cell treatment to be effective. CAR T cells target bone marrow and other organs that make up the lymphatic system in individuals with non-solid malignancies such lymphomas. However, this is not always the case with solid tumours, such as breast cancer. Even if they do move to the tumour, the nature of the microenvironment around such tumours prevents them from persisting and expanding there, according to Serody.

Serody and his colleagues set out to find a way to steer the lab-expanded cells toward solid tumours. They concentrated on Th17 and Tc17 cells, which have been shown to stay longer in the microenvironment surrounding a tumour, owing to their superior survival capacities. They used two small compounds that can stimulate an immune response to promote the accumulation of Th17 and Tc17 cells around solid tumours: the stimulator of interferon genes (STING) agonists DMXAA and cGAMP.

Because it does not activate human STING, DMXAA, which worked well in the investigator’s mouse research, has not shown to be beneficial in human clinical trials. However, the other STING agonist, cGAMP, does activate human STING and has been shown to improve human immunity. It’s also effective in mice.

In Serody’s tests, mice injected with cGAMP showed increased T cell proliferation and migration to the tumour location. As a result, tumour growth was significantly slowed and survival was improved.

Apply for CAR T-Cell therapy


Apply Now

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy